Chardan Capital initiated coverage on shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) in a report published on Friday, Marketbeat Ratings reports. The firm issued a neutral rating on the biopharmaceutical company’s stock.
Several other brokerages have also recently issued reports on DRNA. ValuEngine upgraded shares of Dicerna Pharmaceuticals from a sell rating to a hold rating in a report on Friday, February 2nd. BidaskClub upgraded shares of Dicerna Pharmaceuticals from a hold rating to a buy rating in a report on Thursday, January 25th. Zacks Investment Research cut shares of Dicerna Pharmaceuticals from a hold rating to a sell rating in a report on Thursday, February 1st. SunTrust Banks initiated coverage on shares of Dicerna Pharmaceuticals in a report on Monday, February 5th. They issued a buy rating and a $13.00 target price for the company. Finally, Stifel Nicolaus upped their target price on shares of Dicerna Pharmaceuticals from $10.00 to $17.00 and gave the company a buy rating in a report on Friday. One investment analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Dicerna Pharmaceuticals has an average rating of Buy and an average target price of $11.21.
Dicerna Pharmaceuticals (DRNA) opened at $14.12 on Friday. Dicerna Pharmaceuticals has a twelve month low of $2.52 and a twelve month high of $15.00. The company has a market cap of $730.95, a P/E ratio of -3.87 and a beta of 2.18.
In other Dicerna Pharmaceuticals news, Director Bain Capital Life Sciences Inv purchased 285,000 shares of Dicerna Pharmaceuticals stock in a transaction that occurred on Monday, December 18th. The stock was purchased at an average price of $7.00 per share, for a total transaction of $1,995,000.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 29.41% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in DRNA. Northern Trust Corp raised its position in Dicerna Pharmaceuticals by 6.1% in the 2nd quarter. Northern Trust Corp now owns 36,219 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 2,094 shares during the last quarter. Vanguard Group Inc. raised its position in Dicerna Pharmaceuticals by 4.5% in the 2nd quarter. Vanguard Group Inc. now owns 340,327 shares of the biopharmaceutical company’s stock valued at $1,078,000 after purchasing an additional 14,517 shares during the last quarter. First Manhattan Co. purchased a new stake in Dicerna Pharmaceuticals in the 4th quarter valued at $3,865,000. Emerald Advisers Inc. PA purchased a new stake in Dicerna Pharmaceuticals in the 4th quarter valued at $266,000. Finally, Monashee Investment Management LLC purchased a new stake in Dicerna Pharmaceuticals in the 4th quarter valued at $1,878,000. Hedge funds and other institutional investors own 75.49% of the company’s stock.
Dicerna Pharmaceuticals Company Profile
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.